Current status of gene therapy strategies to treat HIV/AIDS. (Q36143446)

12 August 2017

1 reference

title

Current status of gene therapy strategies to treat HIV/AIDS. (English)

1 reference

12 August 2017

0 references

5

Vicente Planelles

1 reference

12 August 2017

6

Roger J Pomerantz

1 reference

12 August 2017

2

Ramesh Akkina

1 reference

12 August 2017

David S Strayer

1

1 reference

12 August 2017

Bruce A Bunnell

3

1 reference

12 August 2017

Boro Dropulic

4

1 reference

12 August 2017

John J Rossi

7

1 reference

12 August 2017

John A Zaia

8

1 reference

12 August 2017

1 June 2005

1 reference

12 August 2017

1 reference

12 August 2017

11

1 reference

12 August 2017

823-842

1 reference

12 August 2017

6

1 reference

Reduced antiretroviral drug susceptibility among patients with primary HIV infection

12 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Incidence and impact of resistance against approved antiretroviral drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Resistance of HIV-1 to multiple antiretroviral drugs in France: a 6-year survey (1997-2002) based on an analysis of over 7000 genotypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Transmission of HIV-1 drug resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Persistence of HIV-1 resistance in lymph node mononuclear cell RNA despite effective HAART.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Rapid activation of lymph nodes and mononuclear cell HIV expression upon interrupting highly active antiretroviral therapy in patients after prolonged viral suppression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Acute human immunodeficiency virus replication causes a rapid and persistent impairment of Vgamma9Vdelta2 T cells in chronically infected patients undergoing structured treatment interruption

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Genetic characterization of rebounding human immunodeficiency virus type 1 in plasma during multiple interruptions of highly active antiretroviral therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

The lymphocyte HIV reservoir in patients on long-term HAART is a memory of virus evolution

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Gene therapy using a simian virus 40-derived vector inhibits the development of in vivo human immunodeficiency virus type 1 infection of severe combined immunodeficiency mice implanted with human fetal thymic and liver tissue.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Optimization of ex vivo activation and expansion of macaque primary CD4-enriched peripheral blood mononuclear cells for use in anti-HIV immunotherapy and gene therapy strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Gene therapy. Intracellular immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Gene therapy for infectious diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

HIV-1 Gag mutants can dominantly interfere with the replication of the wild-type virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Expression of a protective gene-prolongs survival of T cells in human immunodeficiency virus-infected patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Enhanced T cell engraftment after retroviral delivery of an antiviral gene in HIV-infected individuals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Studies on the effect of the combined expression of anti-tat and anti-rev genes on HIV-1 replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Protection of primary human T cells from HIV infection by Trev: a transdominant fusion gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Conditional reduction of human immunodeficiency virus type 1 replication by a gain-of-herpes simplex virus 1 thymidine kinase function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Long-term inhibition of clinical and laboratory human immunodeficiency virus strains in human T-cell lines containing an HIV-regulated diphtheria toxin A chain gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Construction of a novel virus that targets HIV-1-infected cells and controls HIV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

A CXCR4/CD4 Pseudotype Rhabdovirus That Selectively Infects HIV-1 Envelope Protein-Expressing Cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Phenotypic knockout of HIV type 1 chemokine coreceptor CCR-5 by intrakines as potential therapeutic approach for HIV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Inactivation of HIV-1 chemokine co-receptor CXCR-4 by a novel intrakine strategy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Anti-HIV type 1 activity of wild-type and functional defective RANTES intrakine in primary human lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Intrakines--evidence for a trans-cellular mechanism of action

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Blockade of human immunodeficiency virus type 1 production in CD4+ T cells by an intracellular CD4 expressed under control of the viral long terminal repeat

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Design, intracellular expression, and activity of a human anti-human immunodeficiency virus type 1 gp120 single-chain antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Potent inhibition of human immunodeficiency virus type 1 replication by an intracellular anti-Rev single-chain antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Intracellular antibodies (intrabodies) for gene therapy of infectious diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Inhibition of human immunodeficiency virus replication by antisense oligodeoxynucleotides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Pathogenesis of infection with human immunodeficiency virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Inhibition of HIV replication by sense and antisense rev response elements in HIV-based retroviral vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

RETRACTED: Phosphate-methylated DNA aimed at HIV-1 RNA loops and integrated DNA inhibits viral infectivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Specific inhibition of human immunodeficiency virus type 1 replication by antisense oligonucleotides: an in vitro model for treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Overexpression of TAR sequences renders cells resistant to human immunodeficiency virus replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Gene therapy for AIDS using retroviral mediated gene transfer to deliver HIV-1 antisense TAR and transdominant Rev protein genes to syngeneic lymphocytes in HIV-1 infected identical twins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Ribozymes as potential anti-HIV-1 therapeutic agents.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Ribozymes as therapies for AIDS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Inhibition of human immunodeficiency virus type 1 expression by a hairpin ribozyme

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Characterization of anti-CCR5 ribozyme-transduced CD34+ hematopoietic progenitor cells in vitro and in a SCID-hu mouse model in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Rev-binding aptamer and CMV promoter act as decoys to inhibit HIV replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Endogenous expression of a high-affinity pseudoknot RNA aptamer suppresses replication of HIV-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Multivalent anti-CCR ribozymes for stem cell-based HIV type 1 gene therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Inhibition of CCR5-dependent HIV-1 infection by hairpin ribozyme gene therapy against CC-chemokine receptor 5.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Suppression of chemokine receptor expression by RNA interference allows for inhibition of HIV-1 replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

RNA interference meets HIV-1: will silence be golden?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Modulation of HIV-1 replication by RNA interference

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Human immunodeficiency virus type 1 escapes from RNA interference-mediated inhibition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Combination genetic therapy to inhibit HIV-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Human immunodeficiency virus type 1 escape from RNA interference

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Inhibition of HIV-1 infection by lentiviral vectors expressing Pol III-promoted anti-HIV RNAs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Potent suppression of HIV type 1 infection by a short hairpin anti-CXCR4 siRNA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

siRNA-directed inhibition of HIV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

The effect of genetic variation in chemokines and their receptors on HIV transmission and progression to AIDS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Novel interfering bifunctional molecules against the CCR5 coreceptor are efficient inhibitors of HIV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Lentiviral transduction of human T-lymphocytes with a RANTES intrakine inhibits human immunodeficiency virus type 1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Functional deletion of the CCR5 receptor by intracellular immunization produces cells that are refractory to CCR5-dependent HIV-1 infection and cell fusion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Targeting CCR5 with siRNAs: using recombinant SV40-derived vectors to protect macrophages and microglia from R5-tropic HIV.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Cell-surface expression of CD4 reduces HIV-1 infectivity by blocking Env incorporation in a Nef- and Vpu-inhibitable manner

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

The physiological relevance of CD4 receptor down-modulation during HIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Enhanced CD4 down-modulation by late stage HIV-1 nef alleles is associated with increased Env incorporation and viral replication.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Modulation of different human immunodeficiency virus type 1 Nef functions during progression to AIDS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Inefficient enhancement of viral infectivity and CD4 downregulation by human immunodeficiency virus type 1 Nef from Japanese long-term nonprogressors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Lentiviral vectors interfering with virus-induced CD4 down-modulation potently block human immunodeficiency virus type 1 replication in primary lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Intracellular trafficking of retroviral genomes during the early phase of infection: viral exploitation of cellular pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Active nuclear import of human immunodeficiency virus type 1 preintegration complexes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Nuclear import of HIV-1 intracellular reverse transcription complexes is mediated by importin 7

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Intrinsic immunity: a front-line defense against viral attack

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

TRIM5alpha mediates the postentry block to N-tropic murine leukemia viruses in human cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

The human and African green monkey TRIM5alpha genes encode Ref1 and Lv1 retroviral restriction factor activities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Retrovirus resistance factors Ref1 and Lv1 are species-specific variants of TRIM5alpha

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Inhibition of HIV-1 by an anti-integrase single-chain variable fragment (SFv): delivery by SV40 provides durable protection against HIV-1 and does not require selection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Cofactors for human immunodeficiency virus type 1 cDNA integration in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

HIV-1 integrase forms stable tetramers and associates with LEDGF/p75 protein in human cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

LEDGF/p75 determines cellular trafficking of diverse lentiviral but not murine oncoretroviral integrase proteins and is a component of functional lentiviral preintegration complexes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Identification and characterization of a functional nuclear localization signal in the HIV-1 integrase interactor LEDGF/p75

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Lens epithelium-derived growth factor/p75 prevents proteasomal degradation of HIV-1 integrase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Specificity of interaction of INI1/hSNF5 with retroviral integrases and its functional significance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

RNA interference directed against viral and cellular targets inhibits human immunodeficiency Virus Type 1 replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

SV40-derived vectors provide effective transgene expression and inhibition of HIV-1 using constitutive, conditional,and pol III promoters.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Optimized chimeras between kinase-inactive mutant Cdk9 and truncated cyclin T1 proteins efficiently inhibit Tat transactivation and human immunodeficiency virus gene expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Rev protein and its cellular partners

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

7 January 2021

THE HIV-1 REV PROTEIN

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

HIV-1 Vif Blocks the Antiviral Activity of APOBEC3G by Impairing Both Its Translation and Intracellular Stability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

HIV: a tough viral nut to crack

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

HIV-1 Vpr increases viral expression by manipulation of the cell cycle: a mechanism for selection of Vpr in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Comparison of cell cycle arrest, transactivation, and apoptosis induced by the simian immunodeficiency virus SIVagm and human immunodeficiency virus type 1 vpr genes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

The leader of human immunodeficiency virus type 1 genomic RNA harbors an internal ribosome entry segment that is active during the G2/M phase of the cell cycle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Activation of the ATR-mediated DNA damage response by the HIV-1 viral protein R.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Human immunodeficiency virus type 1 Vpr-mediated G2 arrest requires Rad17 and Hus1 and induces nuclear BRCA1 and gamma-H2AX focus formation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Vpr R77Q is associated with long-term nonprogressive HIV infection and impaired induction of apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Processing and routage of HIV glycoproteins by furin to the cell surface

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Comparative functional role of PC7 and furin in the processing of the HIV envelope glycoprotein gp160

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Endoprotease activities other than furin and PACE4 with a role in processing of HIV-I gp160 glycoproteins in CHO-K1 cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Isolation of the human PC6 gene encoding the putative host protease for HIV-1 gp160 processing in CD4+ T lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

HIV-1 proprotein processing as a target for gene therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Conditional expression of alpha1-antitrypsin delivered by recombinant SV40 vectors protects lymphocytes against HIV.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Mechanisms of alpha1-antitrypsin inhibition of cellular serine proteases and HIV-1 protease that are essential for HIV-1 morphogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Specific incorporation of cyclophilin A into HIV-1 virions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Cyclophilin A modulates the sensitivity of HIV-1 to host restriction factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Mechanisms of enveloped RNA virus budding

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Tsg101 and the vacuolar protein sorting pathway are essential for HIV-1 budding

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

The Protein Network of HIV Budding

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Interferons in the persistence, pathogenesis, and treatment of HIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Multiple Effects of Interferon on HIV-1 Replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Antiviral actions of interferon interferon-regulated cellular proteins and their surprisingly selective antiviral activities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Inhibition of human immunodeficiency virus (HIV) replication by HIV-trans-activated alpha 2-interferon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Direct and cell-mediated effects of interferon-alpha and -gamma on cells chronically infected with HTLV-III.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Activity of interferons alpha, beta, and gamma against human immunodeficiency virus replication in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Interferons and bacterial lipopolysaccharide protect macrophages from productive infection by human immunodeficiency virus in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Interferon-alpha but not AZT suppresses HIV expression in chronically infected cell lines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Recombinant human interferon alfa-A suppresses HTLV-III replication in vitro.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Human alpha- and beta-interferon but not gamma- suppress the in vitro replication of LAV, HTLV-III, and ARV-2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Trans-activated interferon-alpha2 delivered to T cells by SV40 inhibits early stages in the HIV-1 replicative cycle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Inhibition of HIV-1 in the central nervous system by IFN-alpha2 delivered by an SV40 vector.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Karnofsky Memorial Lecture. The immunotherapy and gene therapy of cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Integration of murine leukemia virus DNA depends on mitosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Genetically modified skin fibroblasts persist long after transplantation but gradually inactivate introduced genes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Retrovirus-mediated transfer of human adenosine deaminase gene sequences into cells in culture and into murine hematopoietic cells in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

A human immunodeficiency virus type 1 pol gene-derived sequence (cPPT/CTS) increases the efficiency of transduction of human nondividing monocytes and T lymphocytes by lentiviral vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Human T lymphocytes transduced by lentiviral vectors in the absence of TCR activation maintain an intact immune competence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Lentiviral vectors for gene therapy of HIV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

A conditionally replicating HIV-1 vector interferes with wild-type HIV-1 replication and spread

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Anti-human immunodeficiency virus type 1 gene therapy in human central nervous system-based cells: an initial approach against a potential viral reservoir

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Development of an Rev-independent, minimal simian immunodeficiency virus-derived vector system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Defective lentiviral vectors are efficiently trafficked by HIV-1 and inhibit its replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Enhanced inhibition of human immunodeficiency virus type 1 replication by novel lentiviral vectors expressing human immunodeficiency virus type 1 envelope antisense RNA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Temporal fluctuations in HIV quasispecies in vivo are not reflected by sequential HIV isolations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Virus entry into animal cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

HIV accessory proteins: leading roles for the supporting cast.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Integrated self-inactivating lentiviral vectors produce full-length genomic transcripts competent for encapsidation and integration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

A Rev-independent human immunodeficiency virus type 1 (HIV-1)-based vector that exploits a codon-optimized HIV-1 gag-pol gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Cell-surface expression of influenza haemagglutinin from a cloned DNA copy of the RNA gene.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Use of SV40 to immunize against hepatitis B surface antigen: implications for the use of SV40 for gene transduction and its use as an immunizing agent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Immune responses against SIV envelope glycoprotein, using recombinant SV40 as a vaccine delivery vector

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

A replication-deficient rSV40 mediates liver-directed gene transfer and a long-term amelioration of jaundice in gunn rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Efficient gene transfer to hematopoietic progenitor cells using SV40-derived vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Use of SV40-based vectors to transduce foreign genes to normal human peripheral blood mononuclear cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Inhibition of HIV-1 infection by down-regulation of the CXCR4 co-receptor using an intracellular single chain variable fragment against CXCR4.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Protecting from R5-tropic HIV: individual and combined effectiveness of a hammerhead ribozyme and a single-chain Fv antibody that targets CCR5.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Animal models of HIV-1 disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Human xenograft models for virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Diphtheria toxin A gene-mediated HIV-1 protection of cord blood-derived T cells in the SCID-hu mouse model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

RNA-based anti-HIV-1 gene therapeutic constructs in SCID-hu mouse model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Inhibition of HIV-1 by lentiviral vector-transduced siRNAs in T lymphocytes differentiated in SCID-hu mice and CD34+ progenitor cell-derived macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

siRNAs: a new wave of RNA-based therapeutics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Approaches for the sequence-specific knockdown of mRNA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Bispecific short hairpin siRNA constructs targeted to CD4, CXCR4, and CCR5 confer HIV-1 resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Gene transfer into nonhuman primate hematopoietic stem cells: implications for gene therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Update on the use of nonhuman primate models for preclinical testing of gene therapy approaches targeting hematopoietic cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

The use of nonhuman primate models to improve gene transfer into haematopoietic stem cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Simian immunodeficiency virus infection of monkeys as a model system for the study of AIDS pathogenesis, treatment, and prevention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

The simian immunodeficiency viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Diagnosing primary HIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Predictive value of immunologic and virologic markers after long or short duration of HIV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Necropsy findings in rhesus monkeys experimentally infected with cultured simian immunodeficiency virus (SIV)/delta

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Pathogenic diversity of simian immunodeficiency viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Spectrum of disease in macaque monkeys chronically infected with SIV/SMM.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Substantial differences in specificity of HIV-specific cytotoxic T cells in acute and chronic HIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Dominance of CD8 responses specific for epitopes bound by a single major histocompatibility complex class I molecule during the acute phase of viral infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

The qualitative nature of the primary immune response to HIV infection is a prognosticator of disease progression independent of the initial level of plasma viremia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

CD8(+) lymphocytes from simian immunodeficiency virus-infected rhesus macaques recognize 14 different epitopes bound by the major histocompatibility complex class I molecule mamu-A*01: implications for vaccine design and testing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Analysis of Gag-specific cytotoxic T lymphocytes in simian immunodeficiency virus-infected rhesus monkeys by cell staining with a tetrameric major histocompatibility complex class I-peptide complex

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Phenotypic analysis of antigen-specific T lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Use of overlapping peptide mixtures as antigens for cytokine flow cytometry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Neutralizing antibodies associated with viremia control in a subset of individuals after treatment of acute human immunodeficiency virus type 1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

In vivo migration and function of transferred HIV-1-specific cytotoxic T cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Antiviral effect and ex vivo CD4+ T cell proliferation in HIV-positive patients as a result of CD28 costimulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Differential regulation of HIV-1 fusion cofactor expression by CD28 costimulation of CD4+ T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

The role of co-stimulation in regulation of chemokine receptor expression and HIV-1 infection in primary T lymphocytes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Adoptive transfer of costimulated CD4+ T cells induces expansion of peripheral T cells and decreased CCR5 expression in HIV infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Efficient transduction of human hematopoietic cells with the human multidrug resistance gene 1 via SV40 pseudovirions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

RNA-mediated inhibition of HIV in a gene therapy setting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Stem cell transplantation and gene therapy for HIV-related lymphomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Anti-human immunodeficiency virus hematopoietic progenitor cell-delivered ribozyme in a phase I study: myeloid and lymphoid reconstitution in human immunodeficiency virus type-1-infected patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Autologous stem-cell transplantation for poor-risk and relapsed intermediate- and high-grade non-Hodgkin's lymphoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Immune reconstitution in ADA-SCID after PBL gene therapy and discontinuation of enzyme replacement

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Protection and in vivo selection of hematopoietic stem cells using temozolomide, O6-benzylguanine, and an alkyltransferase-expressing retroviral vector

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

The use of mycophenolate mofetil in transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

A pilot study of the use of mycophenolate mofetil as a component of therapy for multidrug-resistant HIV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

The addition of mycophenolate mofetil to antiretroviral therapy including abacavir is associated with depletion of intracellular deoxyguanosine triphosphate and a decrease in plasma HIV-1 RNA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

7 January 2021

Efficient lentiviral vector-mediated control of HIV-1 replication in CD4 lymphocytes from diverse HIV+ infected patients grouped according to CD4 count and viral load

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Antisense-mediated inhibition of human immunodeficiency virus (HIV) replication by use of an HIV type 1-based vector results in severely attenuated mutants incapable of developing resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Inhibition of human immunodeficiency virus type 1 replication in vitro by a novel combination of anti-Tat single-chain intrabodies and NF-kappa B antagonists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

Inactivation of the Moloney murine leukemia virus long terminal repeat in murine fibroblast cell lines is associated with methylation and dependent on its chromosomal position

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

7 January 2021

Progression to the G1b phase of the cell cycle is required for completion of human immunodeficiency virus type 1 reverse transcription in T cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

7 January 2021

Molecular characterization of human immunodeficiency virus type 1 cloned directly from uncultured human brain tissue: identification of replication-competent and -defective viral genomes

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

7 January 2021

Development of a self-inactivating lentivirus vector.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

7 January 2021

Adeno-associated virus type 2-mediated transduction in primary human bone marrow-derived CD34+ hematopoietic progenitor cells: donor variation and correlation of transgene expression with cellular differentiation.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

7 January 2021

A third-generation lentivirus vector with a conditional packaging system

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.01.020

7 January 2021

10.1016/J.YMTHE.2005.01.020

Identifiers

DOI

1 reference

12 August 2017

1 reference